{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T13:06:43Z","timestamp":1784725603282,"version":"3.55.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"funder":[{"name":"Medizinische Fakult\u00e4t Heidelberg der Universit\u00e4t Heidelberg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatologie"],"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>Ein 42-j\u00e4hriger Zerspanungsmechaniker litt seit 2009 an Morbus Bechterew, der seit 2021 mit Adalimumab 40\u202fmg\u00a0subkutan (s.c.) alle zwei\u00a0Wochen therapiert wurde. Etwa vier\u00a0Jahre sp\u00e4ter entwickelte er R\u00f6tungen und Pusteln an Handtellern und Fu\u00dfsohlen. Es wurden eine Psoriasis pustulosa palmoplantaris und eine Psoriasis vulgaris diagnostiziert. Die Therapie wurde auf Secukinumab 150\u202fmg\u00a0s.c. alle vier\u00a0Wochen umgesetzt, worunter sich der Hautbefund leicht besserte. Dieser Fall demonstriert, dass bei therapieresistenter Psoriasis palmoplantaris auch noch nach Jahren eine Nebenwirkung von Biologika zu ber\u00fccksichtigen ist.<\/jats:p>","DOI":"10.1007\/s00105-026-05747-6","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T12:35:00Z","timestamp":1784723700000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Kutane Nebenwirkungen von Biologika: ein wichtiges Thema auch in der Berufsdermatologie","Cutaneous side effects of biologics: an important topic also in occupational dermatology"],"prefix":"10.1007","author":[{"given":"Angel","family":"Peev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice","family":"Waitek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatevik","family":"Martirosyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Roll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Weisshaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"issue":"3","key":"5747_CR1","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/j.1600-0536.2012.02170.x","volume":"68","author":"E Weisshaar","year":"2013","unstructured":"Weisshaar\u00a0E, Skudlik\u00a0C, Scheidt\u00a0R et\u00a0al (2013) Multicentre study \u2019rehabilitation of occupational skin diseases -optimization and quality assurance of inpatient management (ROQ)\u2019-results from 12-month follow-up. Contact Dermatitis 68(3):169\u2013174","journal-title":"Contact Dermatitis"},{"key":"5747_CR2","doi-asserted-by":"crossref","unstructured":"Bentz P, Eyerich K, Skudlik C, Schr\u00f6der-Kraft C, L\u00f6ffler H, Pf\u00f6hler C, Leitz R, Th\u00f6lken K, Weisshaar E. Molecular Classification in a\u00a0Cohort of Occupational Dermatological Patients: Diagnostic Results and Course of Ability to Work and Sick Leave Over two years. Acta Derm Venereol 2025 (im Druck).","DOI":"10.2340\/actadv.v106.adv-2025-0023"},{"issue":"6","key":"5747_CR3","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s40257-017-0296-7","volume":"18","author":"S Segaert","year":"2017","unstructured":"Segaert\u00a0S, Hermans\u00a0C (2017) Clinical Signs, Pathophysiology and Management of Cutaneous Side Effects of Anti-Tumor Necrosis Factor Agents. Am J Clin Dermatol 18(6):771\u2013787","journal-title":"Am J Clin Dermatol"},{"issue":"12","key":"5747_CR4","doi-asserted-by":"publisher","first-page":"3962","DOI":"10.1093\/rheumatology\/kead318","volume":"62","author":"B Yagiz","year":"2023","unstructured":"Yagiz\u00a0B, Lermi\u00a0N, Coskun\u00a0BN et\u00a0al (2023) The predictors of paradoxical reactions, especially psoriasis, to biologic therapy-findings from the TReasure database: a 5\u2011year follow-up study. Rheumatology 62(12):3962\u20133967. https:\/\/doi.org\/10.1093\/rheumatology\/kead318","journal-title":"Rheumatology (Oxford)"},{"key":"5747_CR5","unstructured":"Thein D, Egeberg A, Skov L, Loft N. Absolute and Relative Risk of New-Onset Psoriasis Associated With Tumor Necrosis Factor\u2011\u03b1 Inhibitor Treatment in Patients With Immune-Mediated Inflammatory Diseases: A\u00a0Danish Nationwide Cohort Study. JAMA Dermatol."},{"issue":"1","key":"5747_CR6","first-page":"178","volume":"42","author":"I Sagonas","year":"2024","unstructured":"Sagonas\u00a0I, Iliopoulos\u00a0G, Baraliakos\u00a0X, Daoussis\u00a0D (2024) Anti-TNF\u2011\u03b1 induced paradoxical psoriasis in patients with ankylosing spondylitis: a systematic review. Clin Exp Rheumatol 42(1):178\u2013184","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"5747_CR7","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.jaad.2016.08.012","volume":"76","author":"G Brown","year":"2017","unstructured":"Brown\u00a0G, Wang\u00a0E, Leon\u00a0A et\u00a0al (2017) Tumor necrosis factor\u2011\u03b1 inhibitor-induced psoriasis: Systematic review of clinical features, histopathological findings, and management experience. J\u00a0Am Acad Dermatol 76(2):334\u2013341","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"5747_CR8","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1080\/09546630802441234","volume":"20","author":"JM Ko","year":"2009","unstructured":"Ko\u00a0JM, Gottlieb\u00a0AB, Kerbleski\u00a0JF (2009) Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J\u00a0Dermatolog Treat 20(2):100\u2013108. https:\/\/doi.org\/10.1080\/09546630802441234","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"5747_CR9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/cup.13055","volume":"45","author":"C Deubelbeiss","year":"2018","unstructured":"Deubelbeiss\u00a0C, Kolios\u00a0AGA, Anzengruber\u00a0F et\u00a0al (2018) TNF\u03b1 and IL-17A are differentially expressed in psoriasis-like vs eczema-like drug reactions to TNF\u03b1 antagonists. J\u00a0Cutan Pathol 45(1):23\u201328","journal-title":"J Cutan Pathol"},{"issue":"11","key":"5747_CR10","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1007\/s00296-024-05647-9","volume":"44","author":"N Chaitidis","year":"2024","unstructured":"Chaitidis\u00a0N, Papadopoulou\u00a0Z, Varvara\u00a0ST, Panagiotidis\u00a0M, Katsigianni\u00a0I, Sakellariou\u00a0GT (2024) Paradoxical psoriasis induced by IL-17 inhibitors: a case series of patients with axial spondyloarthritis and a systematic literature review. Rheumatol Int 44(11):2659\u20132668","journal-title":"Rheumatol Int"}],"container-title":["Die Dermatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-026-05747-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-026-05747-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-026-05747-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T12:35:03Z","timestamp":1784723703000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-026-05747-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":10,"alternative-id":["5747"],"URL":"https:\/\/doi.org\/10.1007\/s00105-026-05747-6","relation":{},"ISSN":["2731-7005","2731-7013"],"issn-type":[{"value":"2731-7005","type":"print"},{"value":"2731-7013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"assertion":[{"value":"23 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.\u00a0Peev, M.\u00a0Waitek, T.\u00a0Martirosyan, P.\u00a0Roll und E.\u00a0Weisshaar geben an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patient\/-innen zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern\/Vertreterinnen eine schriftliche Einwilligung vor.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}